the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy

Inclusion Criteria: * Patients aged 3-18 years with intractable childhood-onset epilepsy. * All patients are diagnosed to have drug-resistant epilepsy (refractory epilepsy) according to the ILAE definition. * The subject is willing and able to comply with the study requirements Exclusion Criteria: * Any metabolic conditions that might increase the risks associated with trial participation or investigational product administration, such as hepatic enzyme elevation greater than twice normal and/or a GFR \< 60 mL/min/1.73 m2 or electrolyte imbalance. * Patients with Known allergy to N-acetyl cysteine. * Patients taking antioxidant and/or anti-inflammatory medications